Literature DB >> 3199318

Linear and nonlinear system approaches in pharmacokinetics: how much do they have to offer? II. The response mapping operator (RMO) approach.

P Veng-Pedersen1.   

Abstract

The description of the relationship between different responses measured simultaneously in the same subject is commonly described in terms of specific pharmacokinetic models such as linear compartmental models. An alternative system approach involving response mapping operators (RMOs) is presented. The theoretical and mathematical basis of the RMO approach are derived. The assumptions, limitations, and practical significance of the RMO approach are discussed. The derivation of the RMO is illustrated with several examples. An algorithm and computer program for implementing the RMO in a routine manner is presented. The usage of the computer programs RMO and MAP presented are demonstrated using the pharmacokinetics of trimazosin and cefamandole in humans as examples. The RMO approach offers a new and powerful tool in pharmacokinetic analysis, which allows the investigator to approach certain problems in an objective, rational way without getting involved in specific pharmacokinetic modeling.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3199318     DOI: 10.1007/bf01062384

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  8 in total

1.  Curve fitting and modeling in pharmacokinetics and some practical experiences with NONLIN and a new program FUNFIT.

Authors:  P V Pedersen
Journal:  J Pharmacokinet Biopharm       Date:  1977-10

2.  A system approach to pharmacodynamics. I: Theoretical framework.

Authors:  P Veng-Pedersen; W R Gillespie
Journal:  J Pharm Sci       Date:  1988-01       Impact factor: 3.534

3.  A note on appropriate constraints on the initial input response when applying deconvolution.

Authors:  P Veng-Pedersen; W R Gillespie
Journal:  J Pharmacokinet Biopharm       Date:  1986-08

4.  Linear and nonlinear system approaches in pharmacokinetics: how much do they have to offer? I. General considerations.

Authors:  P Veng-Pedersen
Journal:  J Pharmacokinet Biopharm       Date:  1988-08

5.  Pharmacokinetic and pharmacodynamic modelling of trimazosin and its major metabolite.

Authors:  P A Meredith; A W Kelman; H L Elliott; J L Reid
Journal:  J Pharmacokinet Biopharm       Date:  1983-08

6.  Pharmacokinetics of cefamandole using a HPLC assay.

Authors:  N S Aziz; J G Gambertoglio; E T Lin; H Grausz; L Z Benet
Journal:  J Pharmacokinet Biopharm       Date:  1978-04

7.  General treatment of linear pharmacokinetics.

Authors:  P V Pedersen
Journal:  J Pharm Sci       Date:  1978-02       Impact factor: 3.534

8.  A system approach to pharmacodynamics. II: Glyburide pharmacodynamics and estimation of optimal drug delivery.

Authors:  W R Gillespie; P Veng-Pedersen; E J Antal; J P Phillips
Journal:  J Pharm Sci       Date:  1988-01       Impact factor: 3.534

  8 in total
  6 in total

1.  Neural networks in pharmacodynamic modeling. Is current modeling practice of complex kinetic systems at a dead end?

Authors:  P Veng-Pedersen; N B Modi
Journal:  J Pharmacokinet Biopharm       Date:  1992-08

2.  Estimation of amobarbital plasma-effect site equilibration kinetics. Relevance of polyexponential conductance functions.

Authors:  J W Mandema; P Veng-Pedersen; M Danhof
Journal:  J Pharmacokinet Biopharm       Date:  1991-12

3.  Stepwise determination of multicompartment disposition and absorption parameters from extravascular concentration-time data. Application to mesoridazine, flurbiprofen, flunarizine, labetalol, and diazepam.

Authors:  J G Wagner; D A Ganes; K K Midha; I Gonzalez-Younes; J C Sackellares; L D Olson; M B Affrime; J E Patrick
Journal:  J Pharmacokinet Biopharm       Date:  1991-08

4.  Validation of a variable direction hysteresis minimization pharmacodynamic approach: cardiovascular effects of alfentanil.

Authors:  N B Modi; P Veng-Pedersen
Journal:  Pharm Res       Date:  1994-01       Impact factor: 4.200

5.  Pharmacokinetic differentiation of drug candidates using system analysis and physiological-based modelling. Comparison of C.E.R.A. and erythropoietin.

Authors:  Peter Veng-Pedersen; Kevin J Freise; Robert L Schmidt; John A Widness
Journal:  J Pharm Pharmacol       Date:  2008-10       Impact factor: 3.765

6.  A system-approach method for the adjustment of time-varying continuous drug infusion in individual patients: a simulation study.

Authors:  Mária Durisová; Ladislav Dedík
Journal:  J Pharmacokinet Pharmacodyn       Date:  2002-12       Impact factor: 2.745

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.